NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Wednesday that its sales in the third quarter fell 16 percent year over year.

Total sales for the three months came in at $6.6 million, compared to $7.9 million a year ago. While the Omaha, Neb.-based company saw a change in mix to higher priced lab tests and higher contract revenues associated with a collaboration agreement, it wasn't enough to offset a decrease in laboratory services to $4.1 million from $4.7 million, and a drop in diagnostic tools sales to $2.5 million from $3.2 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
07
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.